CTRI/2020/09/027638招募中未知
â??A descriptive study of PIK3CA mutations in patients with HR+/Her2-advanced breast cancerâ?? (PIK3CA Registry Study)
ovartis Healthcare Pvt Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •Written patient informed consent must be obtained prior to any data collection and
- •sample shipment to a local designated laboratory.
- •2. Patient is an adult male or female (>= 18 years of age).
- •3. Confirmed advanced (locoregionally recurrent not amenable to curative therapy or
- •metastatic) breast cancer.
- •4. Patient has a histologically and/or cytologically confirmed diagnosis of ER+ and/or
- •PgR+ , as well as Her2- breast cancer by local laboratory.
- •5. Patient has available a tumor tissue (archival or fresh) to be sent to a local lab for
- •PIK3CA testing.
- •6. Any lines of treatment for metastatic setting will be allowed.
排除标准
- •Non applicable
研究者
相似试验
招募中
不适用
A clinical trial to study the effectiveness and tolerability of Alpelisib in patients with HR-positive and HER2-negative advanced breast cancer/metastatic breast cancer in IndiaCTRI/2021/10/037292ovartis Healthcare Pvt Limited
招募中
不适用
PIK3CA Mutational Status AssessmentBreast Cancer MetastaticNCT06706570European Institute of Oncology100
终止
不适用
Biomarkers in Tissue Samples From Older Women With Breast CancerBreast CancerNCT01346579Alliance for Clinical Trials in Oncology505
已完成
不适用
Study of PIK3CA Mutations and Effectiveness and Tolerability Outcomes of Alpelisib in Real-worldBreast CancerNCT05022342Novartis Pharmaceuticals595
进行中（未招募）
不适用
Study of genetic alterations in patients with Keratoconus using DNA sequencing technique dnaKeratoconus, mutation, geneC11.204.627RBR-624vfvniversidade Federal de Goias